

# A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Pfizer
Enrollment	200 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Age:
- years of age or older (or the minimum legal adult age as defined per local regulations, whichever is greater) at screening.
- Disease Characteristics:
- Participants must meet the following Chronic Spontaneous Urticaria (CSU) criteria:
  - a. Chronic spontaneous urticaria diagnosis for e3 months at the time of screening (with the onset date assessed by the Investigator based on all available records) b. Diagnosis of CSU inadequately controlled by second generation antihistamine (sgAH) at the time of randomization, defined as: (i) The presence of itch and hives for e6 consecutive weeks prior to screening despite the use of sgAH during this time period.
- ... and 3 more (see full listing online)

### Exclusion (30)

- Medical Conditions:
- Medical conditions pertaining to CSU and other diseases/conditions affecting the skin
- Urticaria is solely due to inducible urticaria.
- Active dermatologic diseases (or conditions) other than chronic urticaria, with urticaria wheals or angioedema symptoms, including but not limited to urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema (eg, due to Complement 1 (C1) inhibitor deficiency).
- Any other active skin disease associated with chronic itching that might influence, in the investigator's opinion, the study evaluations and results (eg, atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.).
- ... and 25 more (see full listing online)

## Locations (2 total)

---

Revival Research Institute, LLC, Troy, Michigan, United States  
Allergy, Asthma and Clinical Research, Oklahoma City, Oklahoma, United States